Interesting, was not really aware of how this "nocebo-effect" can affect a persons perception and feelings on a corona vaccination...
I read this yesterday and did a little investigating. Most people in the control group where given shots and reported side affects. Put a piece of metal into your arm and see if there is an effect. This study is nonsense!
Side effects imaginary? I don't believe it. . Wife and I had two shots of AstraZeneca. Both times we felt tired next day and rested but no big deal. For our booster we both had Moderna and within 6-8 hours our temperatures were up. Woke up in the night shivering so bad I could hardly stand up. Spent next day in bed.
The good news they seem to work... Our vaccinated twins caught covid just before Christmas, confirmed by multiple LFT and PCR. However neither my wife or I caught it from them despite living together and us looking after them for a week. Normally we catch every cold they bring home. Way to go science.
No Evidence to Give COVID-19 Booster Dose to Healthy Children & Adolescents: WHO Chief Science Scientist Soumya Swaminathan
Soumya Swaminathan, chief scientist for the World Health Organization (WHO), went on the record yesterday downplaying any indication that healthy adolescents or children are targets for the COVID-19 booster doses suggesting a possible divergence of opinion between the medical establishment in some of the richer nations and the global health agency charged with implementing a mass COVID-19 vaccination scheme targeting at least 70% of eligible populations by mid-2022.
During a brief press briefing the WHO head scientist declared, “There is no evidence right now that healthy children or healthy adolescents need boosters. No evidence at all.”
While in select wealthy countries such as the United States, England and Israel medical establishments simply recommend boosters the WHO’s mandate and point of view necessitates a different paradigm. For example, in much of sub-Saharan Africa less than 10% of entire populations are vaccinated against COVID-19. Why not send surplus doses to these nations the WHO head might contemplate.
On the other hand, pharmaceutical company manufactures may have financial incentives to see more consumption of doses in wealthy countries because that would lead to a higher probability of new orders, satisfying investor sentiment, goes the thinking.
More Research Necessary
Based on the WHO mandate the heads of the organization suggest more evidence is needed before even third boosts are suggested in healthy young populations. IN the meantime, Israel is already moving to a fourth booster dose in just over twelve months since the first vaccine dose targeting the wildtype version of SARS-CoV-2. Since then, a couple problematic variants emerged including Delta and now Omicron which seems to evade all the vaccines more easily. Highly transmissible thus far accumulating data points to a less severe disease with less death. Of course, this could change quickly. The WHO chief scientist reminded all the group likes to follow “science” in a signal they would like to keep away from other political or economic considerations.
Booster Central
In the land of the Pharma lobby, from the USA to the UK boosters are handed out far more easily. For example, the FDA recently gave the greenlight that youngsters aged 12 and up can receive the Pfizer booster timed five months after the last jab. This changed from the previous six month duration required.
The U.S. Centers for Disease Control and Prevention (CDC) reported CDC COVID Data Tracker recently that 81 million eligible people in the United States have already received a booster. TrialSite reported recently that over 50% of the entire Israel population has already received a third boost. While infection rates skyrocket in both America and Israel luckily thus far the death rates remain far lower than previous surges. The hope is that this trend will continue
How does Omicron spread so fast? A high viral load isn’t the answer
Data on viral levels point to immune evasion as a cause of the variant’s transmissibility.
In countries around the world, Omicron has rapidly surged past other variants to become the dominant SARS-CoV-2 strain. Now, two studies show that the variant has achieved success despite causing viral levels in the body that are similar to — or lower than — those of its main competitor, the Delta variant1,2.
The results suggest that Omicron’s hyper-transmissibility does not stem from the release of large amounts of virus from infected people. Instead, the best explanation for its lightning-fast spread is its ability to evade SARS-CoV-2 immunity caused by either vaccination or past infection, says Emily Bruce, a virologist at the University of Vermont in Burlington.
The studies have not yet been peer reviewed.
Heavy load
Previous research has hinted that, compared with infections earlier in the pandemic, Delta-variant infections lead to a higher ‘viral load’, the amount of virus in an infected person. This is often measured using a polymerase chain reaction (PCR) test, which provides an index of the quantity of viral RNA in the body.
To compare the viral loads linked to the ever-changing cast of SARS-CoV-2 variants, Yonatan Grad, an infectious-disease specialist at the Harvard T. H. Chan School of Public Health in Boston, Massachusetts, and his co-authors drew on data from the National Basketball Association, the organization responsible for professional basketball in North America1. The league conducts frequent COVID-19 testing of its players and personnel.
The researchers studied PCR-test results of nose and throat swabs collected from infected individuals and found that those who had Delta had a slightly higher peak viral load than did those with Omicron. “I was really not expecting to see that,” says Grad. After all, in only two months, Omicron replaced Delta as the dominant cause of US COVID-19 cases.
Beyond Omicron: what’s next for COVID’s viral evolution
Benjamin Meyer, a virologist at the University of Geneva in Switzerland, says he too was stunned by Grad’s results. “Naturally, you’d think that higher transmissibility must cause a higher viral load,” he says.
Meyer and his colleagues took the study a step farther: rather than measuring only viral RNA, they also measured the number of infectious virus particles on swabs collected from a separate group of almost 150 infected people2. This more stringent method found no significant difference between the viral loads of vaccinated individuals infected with Omicron and those infected with Delta.
Isolation exit
The findings have implications for government policies on isolation after infection. Meyer’s team examined samples from people who had been vaccinated but nonetheless became infected with Delta. They found that about half of the samples still held infectious virus five days after the individuals tested positive. Grad and his colleagues found that five days after an initial positive test for Omicron, about half of tested individuals had viral loads high enough that they were probably still infectious.
Such results are concerning, Grad says, because guidelines published by the US Centers for Disease Control and Prevention (CDC) allow people infected with the virus to end their isolation five days after either testing positive or experiencing their first symptoms. The guidelines specify that people who have exited isolation must continue to wear a mask around others for five more days, but do not require a negative COVID-19 test to end isolation. The CDC did not respond to Nature with any comment by press time.
Omicron has made public-health decisions all the more difficult, Grad says. He and his colleagues also found more variability in viral load in individuals infected with Omicron than in people infected with Delta. “That means there’s no clear ‘one size fits all’ approach,” he says.
Side effects imaginary? I don't believe it. . Wife and I had two shots of AstraZeneca. Both times we felt tired next day and rested but no big deal. For our booster we both had Moderna and within 6-8 hours our temperatures were up. Woke up in the night shivering so bad I could hardly stand up. Spent next day in bed.
The good news they seem to work... Our vaccinated twins caught covid just before Christmas, confirmed by multiple LFT and PCR. However neither my wife or I caught it from them despite living together and us looking after them for a week. Normally we catch every cold they bring home. Way to go science.
Booster effectiveness in the NL (fresh data from past weeks...) to prevent severe illness and ICU admission:
After a booster vaccination, the chance that a person infected with the coronavirus SARS-CoV-2 would be admitted to hospital was 33 times lower than for an unvaccinated person, and 5 times lower than for a person who had completed the basic series without a booster. The chance of ICU admission was 50 times lower after a booster compared to someone who is unvaccinated, and 4 times lower than for someone who had completed the basic series without a booster.*
Interesting, was not really aware of how this "nocebo-effect" can affect a persons perception and feelings on a corona vaccination...
You might want to send that article to Kyle. I bet he will disagree with it.
While the world waits for these very easy to tweak mRNA vaccines, some companies are actually moving forward,
Swiss researchers launch trial for COVID "patch" vaccine
LAUSANNE, Switzerland, Jan 19 (Reuters) - Swiss medical researchers said on Wednesday they have launched an early-stage study to test a next-generation COVID-19 vaccine candidate which would be administered via an arm patch, the latest to look at alternative methods of giving injections.
Unlike conventional vaccines that stimulate antibody production, the new PepGNP-Covid19 vaccine candidate focuses on T-cells, which are responsible for cellular immunity, to eliminate cells infected by the virus and prevent it from replicating.
British company Emergex Vaccines Holding Ltd developed the potential vaccine, while Unisanté medical research centre in Lausanne in collaboration with the city's CHUV hospital will run the trial, which started on Jan. 10.
Professor Blaise Genton, head of the study, said this cellular immunity generates so-called "memory cells", which could make the vaccine more durable and could be better than others at protecting against potential variants of the virus.
The possible vaccine will be administered via micro-needles in the patch that are less than one millimetre deep that they hope will provide long-term immunity from COVID-19 and do away with the need for seasonal booster shots.
"With this new vaccine that generates this cellular immunity we hope to have a longer period of protection ... we don't know yet, but it could be one year, two years, three years," Genton told Reuters.
To administer the vaccine, the patch will be pressed against the skin briefly and then removed.
The study is the first in the world with the new candidate and follows the start last year of another study in Lausanne to assess the safety of a new-generation dengue vaccine that uses the same technology.
Emergex Vaccines Holding Ltd announced in November it would begin the trial of the COVID-19 vaccine. The company did not immediately respond to a request for comment.
Drug companies are developing other ways of delivering vaccines. India's Bharat Biotech and partners Codagenix Inc and India's Serum Instituteis are each testing a nasal COVID-19 vaccine candidate.
The PepGNP-Covid19 researchers started vaccinating 26 volunteers last week and plan to give them two doses each - a base dose and a slightly stronger one. They will follow the volunteers for six months. (Reporting by Cecile Mantovani Writing by Paul Carrel; Editing by Frank Jack Daniel)
Booster effectiveness in the NL
NL is the worst data cheating country since day one of pandemic. Thus just throw all NL studies in the bin.
Facts we know from openly reporting countries like UK/IL. Boosters help nothing = 0 = Nada for Omicron. In Israel the rate for all classes to end up in ICU/to die are the almost the same.
Not so for delta. Today the Zürich hospital did report: https://www.tagesanzeiger.ch/n…en-im-januar-120766219848
All Cov-19 admitted to ICU have delta!!
None have Omicron but there are some other admitted for e.g. stroke that have a on entry detected Omicron infection....
So please be aware that some vaccine terror countries just use data faking for fear mongering purposes.
Already RSA did report that most hospital cases are not due to Omicron but with Omicron.
I hope the 2 clowns here that regularly post crap will finally note that we here since 4 weeks discuss Omicron...
time to dump the present vaccines!!!!!
Breakthrough infections with SARS-CoV-2 omicron despite mRNA vaccine booster dose
The most recent SARS-CoV-2 variant of concern to emerge has been named omicron.1 Its immune evasion potential was predicted by genomic data and has been preliminarily confirmed by observations of an increased incidence of reinfections and breakthrough infections.2 This has triggered calls to intensify vaccination programmes including provision of vaccine booster doses.3
A group of German visitors who had received three doses of SARS-CoV-2 vaccines, including at least two doses of an mRNA vaccine, experienced breakthrough infections with omicron between late November and early December, 2021, while in Cape Town, South Africa. The group consisted of five White women and two White men) with an average age of 27·7 years (range 25–39) and a mean body-mass index of 22·2 kg/m2 (range 17·9–29·4), with no relevant medical history. Four of the individuals were participating in clinical elective training at different hospitals in Cape Town, whereas the others were on vacation. The individuals were members of two unlinked social groups and participated in regular social life in Cape Town, in compliance with applicable COVID-19 protocols. Upon arrival during the first half of November, 2021, each individual tested negative for SARS-CoV-2 by PCR and provided records of complete vaccination, including booster or third, doses administered via intramuscular injection using homologous (n=5) and heterologous (n=2) vaccination courses (appendix p 3).4
• View related content for this article
Six individuals were fully vaccinated with BNT162b2 (Comirnaty, Pfizer–BioNTech, Mainz, Germany), five of whom received a third (booster) dose of BNT162b2 in October or early November, 2021. One individual had received a full dose of CX-024414 (Spikevax, Moderna, Cambridge, MA, USA) in early October, 2021; this was not in line with the European Medicines Agency recommendations at that time, which suggested a half dose to boost healthy individuals.5 The seventh individual received an initial dose of ChAdOx1-S (Vaxzevria, AstraZeneca, Cambridge, UK), followed by a dose of BNT162b2 for completion of primary immunisation, and a booster dose of the same vaccine. Except for the CX-024414 booster, all vaccinations were in accordance with European recommendations.4, 5 The early timepoints of some individuals' primary and booster vaccinations were due to their occupation in the medical field. Nobody reported a history of SARS-CoV-2 infection.
During a marked increase in incidence of SARS-CoV-2 infections in the Western Cape province, these individuals observed onset of respiratory symptoms between Nov 30 and Dec 2, 2021. SARS-CoV-2 infections were diagnosed by ISO 15189-accredited diagnostic laboratories using molecular assays approved by the national regulator.
The investigation was approved by the Health Research Ethics Committees of Stellenbosch University (C21/12/004_COVID-19) and the University of Cape Town (279/2021) and all participants provided informed consent.
We obtained swab and serum samples 2–4 days after onset of symptoms. Futher details of how samples were processed are provided in the appendix (p 2). All patients were placed in domestic isolation and used a daily symptom diary to document the course of disease during the observation period of 21 days.
Illness was classified as mild (n=4) or moderate (n=3; shortness of breath) according to National Institutes of Health COVID-19 Treatment Guidelines. Two individuals were asymptomatic by the end of the observation period (day 21). Blood oxygenation levels (SPO2) remained in the normal range (>94%) without exception and none of the patients required hospitalisation. Prevalence of symptoms over time is provided in the appendix (p 4).
All seven individuals were infected with omicron (PANGO lineage B.1.1.529, Nextstrain clade 21K). Viral loads ranged from 4·07 to 8·22 (mean 6·38) log10 viral RNA copies per mL of swab eluate. Anti-spike antibody levels ranged from 15 000 arbitrary units (AU) per mL to more than 40 000 AU/mL, with a mean of approximately 22 000 AU/mL of serum (appendix p 3).
Robust CD4 and CD8 T-cell responses to SARS-CoV-2 spike, nucleocapsid, and membrane proteins were detected in six of the participants tested after a minimum of 2 weeks after onset of symptoms (appendix p 5), at frequencies of 0·011–0·192% for CD4+ and 0·004–0·079% for CD8+ T cells.
These were the first documented breakthrough infections with the omicron variant in fully vaccinated individuals after receipt of booster vaccine doses. Some of these individuals had received heterologous vaccine doses, in line with emerging global practice. Booster doses were administered 21–37 weeks after the second vaccine doses, and breakthrough infections occurred 22–59 days thereafter. At the onset of their breakthrough infections, all individuals had high levels of viral spike protein binding antibodies, similar to levels reported 4 weeks following second vaccine doses6 and as expected after receipt of booster vaccine doses.7
Viral RNA loads in omicron variant infections have yet to be reported. It remains unknown whether the viral loads observed in our group are different from those in unvaccinated, or differently vaccinated, individuals. During wild-type SARS-CoV-2 infection, an average viral RNA load of 5·83 log10 viral RNA copies per swab was found in samples taken up to day after onset of symptoms,8 with a maximum of 8·85 log10 viral RNA copies per swab. In this group of individuals, an average of 6·38 log10 viral RNA copies per mL of eluted swab was detected, with the highest viral load (8·22 log10) detected on day 4 after onset of symptoms. This suggests that the individuals were infectious, in keeping with the occurrence of infection clusters sparing none of the members of the two groups.
Specific T-cell responses were detected in all participants tested at least 2 weeks after symptom onset, in the range reported after vaccination,9 with additional T-cell responses to the viral nucleocapsid and membrane proteins.
The mild to moderate course of illness suggests that full vaccination followed by a booster dose still provides good protection against severe disease caused by omicron. However, we cannot exclude long-term sequelae of COVID-19. Furthermore, our findings are limited to a low number of individuals in relatively young and otherwise healthy individuals (n=7). This case series adds further evidence that, as predicted, omicron is able to evade immunity induced by mRNA vaccines in vivo. South Africa only recently introduced booster vaccinations for individuals immunised with two doses of BNT162b2, so the presence of this group from Germany presented a unique opportunity to study omicron breakthrough infections in individuals with mRNA vaccine boosters.
In-vitro data suggest lower titres of neutralising antibodies against omicron compared to other SARS-CoV-2 lineages following BNT162b2 vaccination but increased titres after a third dose,10, 11, 12 supporting calls for booster doses while the omicron variant appears to be spreading globally. Our study, however, demonstrates insufficient prevention of symptomatic infection in otherwise healthy individuals who had received three doses of COVID-19 mRNA vaccines.
These findings support the need for updated vaccines to provide better protection against symptomatic infection with omicron13 and emphasise that non-pharmaceutical measures should be maintained. Encouragingly, early data from South Africa suggest maintained if reduced effectiveness of the BNT162b2 vaccine against hospital admission.14
Display MoreNL is the worst data cheating country since day one of pandemic. Thus just throw all NL studies in the bin.
Facts we know from openly reporting countries like UK/IL. Boosters help nothing = 0 = Nada for Omicron. In Israel the rate for all classes to end up in ICU/to die are the almost the same.
Not so for delta. Today the Zürich hospital did report:
All Cov-19 admitted to ICU have delta!!
None have Omicron but there are some other admitted for e.g. stroke that have a on entry detected Omicron infection....
So please be aware that some vaccine terror countries just use data faking for fear mongering purposes.
Already RSA did report that most hospital cases are not due to Omicron but with Omicron.
I hope the 2 clowns here that regularly post crap will finally note that we here since 4 weeks discuss Omicron...
And our Swiss clown ignores that the report from Netherlands talks about the time from end of November til last week, with Omicron in the NL now about 95% of all cases?
Is it so difficult to find somewhere a public statistic or graph that is not faked and cheated, and shows the opposite (or somply what you claim all day long) and post this here?
RiVM: "The Omicron variant has supplanted the Delta variant, according to the RIVM. Omicron causes about 95 percent of new infections, said Van Dissel. "The picture is tilting," Van Dissel noted. He reiterated that Omicron is less likely to lead to hospitalization than Delta. Fewer people become so ill that they need intensive care, but to what extent, Van Dissel cannot say completely. "The percentages are continuously adjusted."
"From 19 November 2021 to 13 January 2022, vaccine effectiveness for people who had received a booster vaccination was 97% against hospital admission and 98% against ICU admission. "
When Japan's latest surge ends, and it will once the virus has reached a saturation point of around 40%, it surely will not be because of vaccination!
Japan's daily COVID cases top 46,000, new record for 3rd straight day
Japan's confirmed daily coronavirus cases on Thursday topped 46,000, setting a new record for the third consecutive day as the rapid spread of the highly transmissible Omicron variant has left the country struggling with what has become the "sixth wave" of infections.
Japan's cumulative total of COVID-19 cases has also topped 2 million since the government confirmed the nation's first COVID-19 case in January 2020.
On Thursday, Tokyo confirmed 8,638 daily coronavirus cases, eclipsing the previous record high of 7,377 registered Wednesday. The seven-day rolling average of new infections stood at 5,386.1 per day in the capital
In an effort to curb the further spread of infections, Prime Minister Fumio Kishida's government decided Wednesday to expand a quasi-state of emergency to Tokyo and other regions.
Japan logged a cumulative total of over 1 million COVID-19 cases in August last year when it was reeling from the "fifth wave" of infections.
Although infection numbers started falling afterward with the progress in vaccination against the virus, there has been another surge in Japan since cases of community transmission of Omicron were confirmed in late December.
Here once more for our vaccine terrorist the actual Israels death by vaxx status. Dark green is 3x/4x vaxx light green is incomplete 2x/3x vaxx....
It is obvious that the vaccinated and boostered just die according the fraction in the population. Of course you always can find a subset where the vaccinated look better e.g. for age 90..92 or any arbitrary subset...You can also include historic data... But we have a 100% new situation.
Israel has chosen the worst vaccine that has a lab confirmed 40..1000x lower performance for Omicron... So a few lucky "vaccinated" (4x gene therapy) in the range of 0..15% will see a tiny benefit...This is also what the infection rate show over time as the vulnerable vaccinated are the first ones selected by the virus. So over time the rate will change a tiny bit in favor of gene therapy (vaccinated).
Interesting change in infection number statistics in Spain (Catalonia): Infection rates with Omicron higher among vaccinated (it is known that vaccinations more or less do not prevent somebody from being infected, but it is of course about preventing from severe illness / death and filling up ICU's...)
"Something similar is observed in the official data coming out of Iceland: the 14-day incidence rate is higher among the vaccinated population who have not received a booster shot than among the unvaccinated (5,600 cases per 100,000 inhabitants, compared to 4,000 in the unvaccinated group). However, the lowest incidence is among Icelanders with three doses.
This coincides with the data emerging from Catalonia: in November the incidence was lower for the vaccinated than for the unvaccinated in all age groups. But since the arrival of omicron, among the under-50 population – a demographic that has received few boosters – the infection rates seem to be higher among the vaccinated"
Here once more for our vaccine terrorist the actual Israels death by vaxx status. Dark green is 3x/4x vaxx light green is incomplete 2x/3x vaxx....
It is obvious that the vaccinated and boostered just die according the fraction in the population. Of course you always can find a subset where the vaccinated look better e.g. for age 90..92 or any arbitrary subset...You can also include historic data... But we have a 100% new situation.
Israel has chosen the worst vaccine that has a lab confirmed 40..1000x lower performance for Omicron... So a few lucky "vaccinated" (4x gene therapy) in the range of 0..15% will see a tiny benefit...This is also what the infection rate show over time as the vulnerable vaccinated are the first ones selected by the virus. So over time the rate will change a tiny bit in favor of gene therapy (vaccinated).
I asked you already to please post something readable... not sure who here can translate this so we can see what the Israel Health Ministry (?) did post in Hebrew. I couldn't find any button to push so I can read this in english....do you have one in your browser?
I assume the graph shows the number of cases, not the rate per million in the relevant patient (unvaxx, double vaxx, boostered?) and age group?
Display MoreBob - I agree with you.
Where we perhaps differ is the way we would approach the problem. I would look for considered scientific evaluation of evidence.
My point about this anecdotal evidence is that it does not sway any sane judgement, but it is good PR and most lay people would weight its merit much higher than any expert trying to work things out.
Drug discovery is a really tough problem in cases where the disease is new and only a few people die. Observational data, historically, has proven to be very poor with large false positives, even when things have not been politicised in the way that ivermectin and hcq were in the pandemic. What we have for ivermectin is a whole load of evidence of differing quality. The question is how you put that evidence together. I am persuaded by the fact that the highest quality evidence (there is a lot of this) is roughly neutral;, and that as you reduce quality the apparent effect gets larger. Roughly neutral does not mean ivermectin does not work, and you can always try different doses, different applications, etc. It is however discouraging and that evidence weights so much higher than anecdoptal stories - of basically zero quality because you know they would exist for drugs that did not work.
And everyone went off HCQ when it showed definite negative results in a big high quality trial.
Id like to see that trial . I believe it took place in a hospital setting well into the infection. I posted two studies a year ago, that had been held back from publication for over 9 months the showed early treatment with hydroxychloroquine, zinc were affective if given within first 3 days of symptoms. Your hospital study waited till almost a week after symptoms started. You probably missed reading those because if I remember correctly you had no response to these postings. Hydroxychloroquine works when used early !
HCQ COVID-19 studies. 371 studies, 276 peer reviewed, 305 comparing treatment and control groups. HCQ is not effective when used very late with high dosages over a long period (RECOVERY/SOLIDARITY), effectiveness improves with earlier usage and improved dosing. Early treatment consistently shows positive effects. Negative evaluations typically ignore treatment time, often focusing on a subset of late stage studies. In Vitro evidence made some believe that therapeutic levels would not be attained, however that was incorrect, e.g. see [Ruiz]. Recently added: Juneja Tyson Atipornwanich McKinnon. HCQ or CQ has been officially adopted for early treatment in all or part of 36 countries (53 including non-government medical organizations). Submit updates/corrections.
the infection rates seem to be higher among the vaccinated"
This is a fact we know since > 4 months from UK data. Nothing new with Omicron. The only effect is that one "vaccine" (Pfizer) fails for >90% where others still work for at least 50%.
"Vaccine" protection against Omicron for younger seems to be lower everywhere. https://www.covid19.admin.ch/d…?vaccStatusAgeRange=20-29
I suspect these just do more tests and have more dangerous encounters (clubs, cinema, parties...)
Also here we have a new trend with Omicron that just now is fully visible the first time.
I asked you already to please post something readable...
Every child can read a graphic....These are absolute numbers. Booster rate in Israel is 60%, no vaxx = 30%!
Rate data is not reliable as you always can fudge the denominator...
Finally found a way to translate the Hebrew site into German and work int the dashboard 
: Servere illness rate in Israel in the last 4 weeks in the age group 60+.
Axctive patients 60+ severe ill in the last 4 weeks (huge difference between unvaxx and vaxx)
New patients in the last 4 weeks 60+ (still a huge factor between unvaxx and vaxx...)
Every child can read a graphic....These are absolute numbers. Booster rate in Israel is 60%, no vaxx = 30%!
Rate data is not reliable as you always can fudge the denominator...
It is of course easier to argue on total numbers (vaxx in hospital are higher due to large vaccination rate for Omicron). But that doesn't change the risk for vaxxed or unvaxxed... if all 60+ are vaccinated we would talk about hospitalisations, severe illness and deaths among fully vaccinated only. You will need th fudge the denominator a lot to come up in the end with a higher risk for vaxx people vs. unvaxx...
As said you can always do subsetting like Israel does since day one. 60+ means nothing as the risk of 60..70 is 1/100 of 80+ and you just dilute the figures or as I said fake the denominator.
Further this data is the rolling average for one month and gives no insight for Omicron that just statistically unfolds since 1 week. (Deaths lag by 2-4 weeks...)
So finally with Omicron the vaccine terrorist loose the game but seem not ready to swallow it...
(Nice to see that you got some help from THH's FM/B mafia team. Best info for me so far....)
